This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.Here is a sample of this item:Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference 2009-11-12 08:01 ET - News Release SAN DIEGO, Nov. 12 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the Lazard Capital Markets 6th Annual Healthcare Conference. The details are as follows:
Lazard Capital Markets 6th Annual Healthcare Conference
Date: Wednesday, November 18, 2009
Time: 1:15pm Eastern Time
Location: St. Regis Hotel, New York
Speaker: Graham Cooper, Chief Financial Officer
About Orexigen Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave(R), has completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second product, Empatic(TM), has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at http://www.Orexigen.com. Orexigen Therapeutics, Inc. The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try,
click here for a free 30 day trial subscription. | 
Top
Print this Page